Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with…
Reset PharmaNovember 1, 2023
Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and…
Reset PharmaNovember 2, 2022
Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s…
Reset PharmaOctober 14, 2021
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and…
Reset PharmaJuly 7, 2021
